Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions

“Cardio-oncology has evolved from being a reactive field focused on managing late cardiac complications to a proactive discipline, emphasizing early detection, prevention and longitudinal care. We now understand that nearly every class of cancer therapy, chemotherapy-targeted agents, immunotherapy and radiotherapy can affect the heart.”

“Over the past two decades, we've learned about the cardiotoxic potential of chemotherapy and are now thinking about it as a long-term issue. This recognition has led to changes in practice across the board. Most notably, this includes the use of a drug called dexrazoxane, which has cardioprotective properties and can be effective when used in combination with anthracyclines, a class of drugs known for their high cardiotoxicity.”